Fort Worth, Tex-based Galderma announces it is launching two Phase III trials focusing on its Restylane brand of dermal fillers.
The first, the Restylane Silk Cannula Study, is a multi-center US study designed to assess the safety and tolerability of Restylane Silk when delivered via a microcannula.
The second trial, the Restylane Lyft Hand Rejuvenation Study, is a randomized, controlled multi-centered US study designed to assess the safety, tolerability, and efficacy of the use of Restylane Lyft to treat loss of volume in the hands. This will reportedly be the first study to examine the use of the hyaluronic acid filler in the hands, explains a media release from the company.
For more information, visit Galderma.
[Source(s): Galderma, PR Newswire]